Trial Evaluating Cardiovascular Outcomes With Sitagliptin
The EC is responsible for the overall management, oversight and reporting of the trial.
|Robert Califf||US||Cardiologist (Joint Chair)|
|Rury Holman||UK||Endocrinologist (Joint Chair)|
|Frans Van de Werf||Belgium||Cardiologist|
The DSMB will help ensure the safety of the trial participants by undertaking regular independent evaluation of trial safety data.
|Marc Pfeffer||US||Cardiologist (Chair)|
The OC is comprised of country lead investigators selected by the Executive Committee, DTU and DCRI. The primary role of the OC is to serve as the interface between the EC and the trial sites and to monitor and supervise the progress of the trial at a regional level.